Does Semaglutide or Tirzepatide Cause Muscle Loss?

Yes, some of the weight a GLP-1 takes off is muscle — that's true of essentially every method of significant weight loss, not a defect unique to these drugs. The real questions are how much, whether the amount is unusual, and what a provider should actually be doing about it. The body-composition substudies buried inside the pivotal trials answer all three.

Every weight-loss method sheds some lean mass — that's the baseline, not the alarm

A 2024 review in *Diabetes, Obesity and Metabolism* that pooled dual-energy X-ray absorptiometry (DXA) data across GLP-1 receptor agonist trials — semaglutide, tirzepatide, and earlier agents — found that most weight-loss interventions lose less than 25% of total weight as fat-free mass, with more aggressive interventions like bariatric surgery losing a higher share¹. GLP-1-based treatments landed at the higher end of that range: percent fat-free-mass loss across 28 trials ran between 20% and 40%, with the majority of studies reporting more than 25%¹. That's real, but it's a matter of degree within the range weight loss generally produces — not a separate category of harm.

What the SURMOUNT-1 body-composition substudy actually measured

The most direct data comes from a 2025 substudy of SURMOUNT-1 that ran DXA scans on 160 participants at baseline and week 72. Tirzepatide produced a −21.3% change in total body weight, made up of a −33.9% change in fat mass and a −10.9% change in lean mass; of the weight actually lost, about 75% was fat and 25% was lean mass — and that roughly 75/25 split held consistent across most clinically relevant subgroups, including the placebo arm². Read that last part carefully: the *proportion* lost as lean mass wasn't dramatically different between tirzepatide and placebo. What differs is the total amount of weight lost — and because tirzepatide produces so much more total weight loss than diet alone typically achieves, the same proportion translates into a bigger absolute number of pounds of lean mass gone. The rate isn't unusually aggressive; the scale of the whole event is.

Why this still deserves real attention

Lean mass matters beyond the scale — it's tied to resting metabolic rate, strength, and functional capacity, especially in people already carrying comorbidities or entering the drug at an older age. A 2026 clinical nutrition review focused specifically on the GLP-1 era: baseline micronutrient inadequacies are common in people with obesity to begin with, and reduced intake plus GI side effects during therapy can make them worse, on top of the absolute lean-mass loss³. That combination — less food, less protein, less muscle-preserving stimulus — is a preventable failure mode, not an inevitable one.

What a good provider actually does about it

The same 2026 review lays out a practical framework worth holding any provider's monitoring plan against: daily protein intake of at least 1.2 g/kg of body weight (up to 1.6 g/kg for appropriate adults without chronic kidney disease), spread across meals at roughly 0.3–0.4 g/kg and 2.5–3 g of leucine per meal; a structured lab panel covering vitamin D, B12, iron studies, folate, zinc, and thiamine in higher-risk patients; progressive resistance training integrated into the plan, not left to chance; and a monitoring schedule using DXA or bioelectrical impedance analysis to actually track the fat-versus-lean split over time, adapted for populations like older adults or those with chronic kidney disease³. A provider that never mentions protein targets, resistance training, or a body-composition check-in over months of treatment is skipping the exact work the evidence says matters.

Where this belongs in a provider's grade

This is precisely what the labs-and-monitoring dimension of the WeighScore exists to catch — whether baseline labs, structured check-ins, and side-effect and body-composition monitoring are actually built into the program or sold as an afterthought. It compounds the point made in do you regain weight after stopping a GLP-1?: this is a long-term relationship, and a provider optimized for a strong first month with no ongoing nutrition or strength guidance is scoring badly on exactly the dimension that protects what you're actually trying to keep — your health, not just a lower number on the scale.

The honest bottom line

GLP-1 therapy does take some muscle along with the fat, at a proportion that's real but not wildly outside what any substantial weight loss produces — the difference is the absolute scale, because these drugs simply move more total weight than most people achieve any other way. The fix is not avoiding the drug; it's protein, resistance training, and monitoring, and a provider that builds those in rather than bolting them on afterward. Compare graded providers on monitoring and oversight in our reviews and comparisons None of this is medical or nutrition advice tailored to you — a clinician or registered dietitian who knows your labs should set your specific targets.